Werewolf Therapeutics Q3 net loss $16.4M, cash $65.7M; key trial updates due Q4 2025

Werewolf Therapeutics, Inc.

2025-Q3 EPS reported -$1.16

Cash and equivalents $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026.
Net loss of $16.4M for Q3 2025, comparable to $16.7M in Q3 2024; R&D expense $11.6M, G&A $4.1M.
WTX-124 received Fast Track Designation; interim Phase 1/1b data and End of Phase 1 FDA meeting expected in Q4 2025.
WTX-330 Phase 1b/2 update and development plan expected in Q4 2025.
WTX-1011 (anti-STEAP1 T-cell engager) in IND-enabling studies; target candidate nomination planned by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.